[go: up one dir, main page]

AR003424A1 - Amidas terapeuticas, composiciones farmaceuticas que las comprenden y compuestos para preparar dichas amidas. - Google Patents

Amidas terapeuticas, composiciones farmaceuticas que las comprenden y compuestos para preparar dichas amidas.

Info

Publication number
AR003424A1
AR003424A1 ARP960102871A AR10287196A AR003424A1 AR 003424 A1 AR003424 A1 AR 003424A1 AR P960102871 A ARP960102871 A AR P960102871A AR 10287196 A AR10287196 A AR 10287196A AR 003424 A1 AR003424 A1 AR 003424A1
Authority
AR
Argentina
Prior art keywords
amides
alkoxy
acyl
aryl
hydroxy
Prior art date
Application number
ARP960102871A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1995/000448 external-priority patent/WO1996040640A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR003424A1 publication Critical patent/AR003424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a amidas terapéuticas de fórmula (I) en la que X es CH2, CO, CS ó SO2, Y es un enlace directo, radicales hidrocarbilenoalifáticos de hasta 20 átomos de carbono que pueden estar monosubstituidos con hidroxi, alcoxi, acilo, aciloxi o arilo, NH y O, con la condición de que si Xes CH2, Y es un enlace directo; Z es (1) H, halo, ciano, (2) hidroxi, alcoxi, tioalquilo, acilo, tiofenilcarbonilo, alcoxicarbonilo, (3) alquilamino,dialquilamino, arilalquilamino siempre que Y no sea O ó NH; (4) vinilo no substituido, arilo, cicloalquilo y derivados benzocondensados del mismo,policicloalquilo, cicloalquenilo, policicloalquenilo; (5) ariloxi, tioarilo, arilo, alcoxi, arilotioalquilo, cicloalquiloxi, cicloalqueniloxi; (6)heterociclilo, siempre que si X es CH2, Z sea H o esté seleccionado de los grupos (4) y (6), donde si Z contiene uno o más anillos, dichos anillos puedenllevar cada uno independientemente de 0 a 4 substituyentes, seleccionados independientemente entre halo, hidroxi, ciano, nitro, oxo,tioxo,aminosulfonilo,fenilo, fenoxi, tiofenilo, tiohalofenilo, bencilo, benciloxi, alquilo, alcoxi, alcoxicarbonilo, tioalquilo, alquilamino, alquilaminocarbonilo, dialquilamino,dialquilaminocarbonilo, dialquilaminoalcoxi, perfluoroalquilo, perfluoroalcoxi, acilo, aciloxi, aciloxialquilo y pirrolidinilo; y las sales farmacéuticamenteaceptables de las mismas. Dichas amidas son útiles para disminuir la secreción de apoB y son útiles en eltratamiento de estados tales como la aterosclerosis.Además, la presente invención se refiere a composiciones farmacéuticas que comprenden a dichas amidas y a compuestos para preparar dichas amidas.
ARP960102871A 1995-06-07 1996-06-03 Amidas terapeuticas, composiciones farmaceuticas que las comprenden y compuestos para preparar dichas amidas. AR003424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Publications (1)

Publication Number Publication Date
AR003424A1 true AR003424A1 (es) 1998-08-05

Family

ID=11004342

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102871A AR003424A1 (es) 1995-06-07 1996-06-03 Amidas terapeuticas, composiciones farmaceuticas que las comprenden y compuestos para preparar dichas amidas.

Country Status (20)

Country Link
US (1) US5919795A (es)
KR (1) KR100225713B1 (es)
AR (1) AR003424A1 (es)
AT (1) ATE233734T1 (es)
AU (1) AU703493B2 (es)
BG (1) BG62442B1 (es)
CO (1) CO4440626A1 (es)
DE (1) DE69529849T2 (es)
DK (1) DK0832069T3 (es)
DZ (1) DZ2045A1 (es)
IL (3) IL135377A0 (es)
MA (1) MA23895A1 (es)
MX (1) MX9709914A (es)
OA (1) OA10363A (es)
RO (1) RO116897B1 (es)
RU (1) RU2141478C1 (es)
TN (1) TNSN96085A1 (es)
TR (1) TR199600481A2 (es)
TW (1) TW476756B (es)
YU (1) YU35296A (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126202A0 (en) * 1996-04-30 1999-05-09 Pfizer Processes and intermediates for preparing 4'-trifluoromethylbiphenyl-2-carboxylic acid [2-(2H-[1,2,4]triazol-3-ylmethyl)-1,2,3,4-tetrahydro-isoquinolin-6-yl]-amide
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
DE60110896T2 (de) * 2000-01-18 2006-01-12 Novartis Ag Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US6953671B2 (en) * 2001-02-23 2005-10-11 The Trustees Of Columbia University In The City Of New York Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action
BR0210616A (pt) 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
AU2003230665B2 (en) * 2002-03-13 2010-02-18 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
WO2005080373A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
AU2006236226B2 (en) * 2005-04-19 2012-07-05 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
NZ571569A (en) * 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
US20100216864A1 (en) * 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
CA2681406A1 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US20110054011A1 (en) * 2007-08-30 2011-03-03 Mccullagh Keith RNA Antagonist Compounds for the Modulation of FABP4/AP2
MY156951A (en) * 2007-10-04 2016-04-15 Santaris Pharma As Micromirs
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
WO2009109665A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
CA2741153A1 (en) * 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Novel phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US9034837B2 (en) * 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
CN103347860A (zh) * 2010-11-15 2013-10-09 Abbvie公司 Nampt抑制剂
SG10201908122XA (en) 2013-06-27 2019-10-30 Roche Innovation Ct Copenhagen As Antisense oligomers and conjugates targeting pcsk9

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
EP0106140B1 (en) * 1982-09-10 1988-08-17 The Wellcome Foundation Limited Benzoic acid derivatives
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
YU23499A (sh) * 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a

Also Published As

Publication number Publication date
IL135376A0 (en) 2001-05-20
AU703493B2 (en) 1999-03-25
RU2141478C1 (ru) 1999-11-20
DE69529849D1 (de) 2003-04-10
AU5478496A (en) 1996-12-19
TW476756B (en) 2002-02-21
DK0832069T3 (da) 2003-04-22
CO4440626A1 (es) 1997-05-07
KR970003589A (ko) 1997-01-28
KR100225713B1 (ko) 1999-10-15
TR199600481A2 (tr) 1996-12-21
MX9709914A (es) 1998-03-31
OA10363A (en) 2001-11-15
US5919795A (en) 1999-07-06
IL135377A (en) 2001-05-20
IL135377A0 (en) 2001-05-20
DZ2045A1 (fr) 2002-07-21
DE69529849T2 (de) 2003-09-04
BG62442B1 (bg) 1999-11-30
ATE233734T1 (de) 2003-03-15
IL135376A (en) 2001-05-20
TNSN96085A1 (fr) 2005-03-15
BG100637A (bg) 1997-03-31
RO116897B1 (ro) 2001-07-30
YU35296A (sh) 1999-06-15
IL135375A0 (en) 2001-05-20
MA23895A1 (fr) 1996-12-31
IL135375A (en) 2001-07-24

Similar Documents

Publication Publication Date Title
AR003424A1 (es) Amidas terapeuticas, composiciones farmaceuticas que las comprenden y compuestos para preparar dichas amidas.
BR9915895A (pt) Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica
HUT58749A (en) Process for producing antiatherosclerotic 2,6-dialkyl-4-silyl-phenol derivatives and compositions containing them
ES2058292T3 (es) Derivados de indol.
EP0354777A3 (en) 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
NZ240050A (en) Substituted piperazine derivatives; pharmaceutical compositions and preparatory processes
UA11100A (uk) Спосіб одержаhhя феhілалкіламіhів або їх фармакологічhо прийhятhих солей
DE3767839D1 (de) Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten.
ES2105549T3 (es) Nuevos derivados fenoxi-isobutiricos sustituidos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DK295989A (da) Insekt- og miderepellanter
ES2043834T3 (es) Un procedimiento para preparar nuevos derivados de androsta-1,4-dien-3-ona sustituida en la posicion 17.
FR2718137B1 (fr) Procédé de préparation de trialcoylsilyl-7 baccatine III.
ES2090238T3 (es) Derivados benzhidriloxietilpiperidilos de acidos alifaticos y su aplicacion en el tratamiento del asma y de sus alergias.
DK64191D0 (da) 4-methyl-5-(2-(4-phenyl-1-piperazinyl)ethyl)thiazolderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende thiazolderivaterne
DK508484A (da) N-substituerede isoquinolinderivater og farmaceutisk praeparat indeholdende dem
ATE35261T1 (de) 4-ethyl-2-hydroxy-3-methyl-2-phenylmorpholin und dessen additionssalze.
DE69521295D1 (de) Triazolderivate
FR2611715B1 (fr) Nouveaux acetamides derives de la dihydro-2,3 phenyl-3 benzofurannone-2, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
ATE137499T1 (de) Verfahren zur herstellung von 2-amino-4- nitrobenzothiazol-derivaten und zwischenprodukte
ATE28071T1 (de) Derivate von 1-(n-(alpha-amino-alphamethylacetyl)-aminophenyl>-2-amino-propanon, verfahren zur herstellung und therapeutische verwendung.